<DOC>
	<DOCNO>NCT02425865</DOCNO>
	<brief_summary>PHASE : IV TYPE OF STUDY : With direct benefit DESCRIPTIVE : multicenter , open-label , uncontrolled trial INCLUSION CRITERIA : Adults moderate severe ulcerative colitis fail corticosteroid immunosupressive therapy , intolerant immunosuppressor . All include patient naïve anti-TNF therapy . Active disease golimumab treatment initiation define MAYO score ≥6 endoscopic sub score ≥2 . OBJECTIVE : To determine proportion patient continue clinical response ( CCR ) endoscopic remission week 108 , discontinuation de-escalation golimumab treatment year 1 subgroup patient continuous clinical response ( CCR ) mucosal heal ( MH ) ( endoscopic Mayo score 0 1 ) week 54 . STUDY DESIGN : Induction Phase : Week 0 : golimumab 200mg- Week 2 : golimumab 100 mg- Week 6 : golimumab 50 mg Phase I : Week 10-Week 54 • Patients primary clinical response* : Standard regimen golimumab 50 mg Q4W ( 100 mg Q4W &gt; 80 kg ) • Patients without primary clinical response* : Optimization 100 mg Q4W ( combination therapy azathioprine &gt; 80 kg switch azathioprine methotrexate already azathioprine golimumab initiation patient know intolerance thiopurines ) • Early escape Week 18 : Primary non-responders still respond week 18 dose optimization Weeks 10 14 consider treatment failure follow ( call visit ) week 54 safety . - Clinical response define decrease baseline Mayo score ≥30 % ≥3 point , accompany either rectal bleeding sub score 0 1 decrease baseline rectal bleeding sub score ≥1 Phase II : Week 54-Week 108 • Patients CCR MH week 54 golimumab 50 mg every 4 week : Stop golimumab continuation thiopurines methotrexate combination therapy • Patients CCR MH week 54 golimumab 100 mg every 4 week : De-escalation 50 mg every 4 week continuation thiopurines methotrexate combination therapy • Restart/Escalate golimumab flare ( defined section 4 protocol ) phase I dose ; 50 mg q4wk 100mg q4wk ( similar phase I regimen )</brief_summary>
	<brief_title>Intermittent Treatment After Reaching taRget With Golimumab ulcErative coliTis - ( TARGET )</brief_title>
	<detailed_description>NUMBER OF PATIENTS : 200 patient INCLUSION PERIOD : 18-24 month STUDY DURATION : 48 54 month MAIN EVALUATION Primary endpoint - Phase I ( week 10-54 ) : proportion patient continuous clinical response ( CCR ) mucosal heal ( MH ; endoscopic Mayo score 0 1 ) week 54 - Phase II ( week 54-108 ) : proportion patient CCR mucosal healing ( endoscopic Mayo score 0 1 ) week 108 , discontinuation dose de-escalation ( 100 50 mg ) golimumab treatment year 1 subgroup patient continuous clinical response ( CCR ) mucosal heal ( endoscopic Mayo score 0 1 ) week 54 Data base lock , data analysis display ( publication ) phase I happen included subject complete 54 week visit . SECONDARY EVALUATION For included patient : - Factors associate treatment success ( see primary endpoint ) - Clinical remission week 54 - Clinical remission week 108 - Partial MAYO score week 54 108 - PRO2 ( Partial Mayo minus PGA ) week 54 108 - Continuous clinical response study inclusion week 108 - Steroid-free clinical remission week 54 108 - Mucosal healing ( endoscopic score MAYO 0-1 ) week 54 108 - Changes faecal calprotectin level baseline week 30 , 54 108 - Colectomy W0 W108 - UC-related hospitalization throughout trial - Histological remission W54 W108 , ( Geboes score ) - PRO : Fatigue ( FACIT ) , IBD Disability Index , QoL ( SHS-IBD VAS ) - PK data ( golimumab trough level antibody golimumab ) - Proportion pt LOR discontinuation dose de-escalation phase II - Predictors LOR discontinuation dose de-escalation phase II - Proportion patient regain response remission flare AND restart golimumab Phase II . For subgroup patient primary non-responders golimumab week 10 , assess efficacy treatment optimization , include percentage patient achieve continuous clinical response endoscopic remission one year .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age ≥ 18 year &lt; 65 year Established diagnosis UC least 3 month Adults moderatelytoseverely active UC inadequate response fail tolerate steroid AND thiopurines ( azathioprine 6mercaptopurine ) , start golimumab . Active disease golimumab treatment initiation define partial MAYO score ≥ 6 endoscopic sub score ≥ 2 . Patients concurrently treat oral corticosteroid receive stable dose ( prednisone 20 mg/day least 2 week ) baseline . Patients allow stable dosage 5aminosalicylates concurrent therapy , 5aminosalicylate use entry criterion trial . Patients allow stable dose thiopurines ( azathioprine 6mercaptopurine stable dose least 4 week ) . Naïve antiTNF therapy , biologics , include antiintegrin antibody ( approved investigational ) . Naïve JAK inhibitor ( approved investigational ) Age 18 65 . People unable give consent ( physical mental state ) . Absence write consent . Pregnancy breastfeed . Patients severe acute colitis patient imminent risk colectomy . History colectomy . Proctitis ( &lt; 20 cm ) . History colonic mucosal dysplasia adenomatous colonic polyp remove . Screening stool study positive enteric pathogen Clostridium difficile toxin . Oral corticosteroid dose &gt; 20 mg prednisone equivalent per day . Any current previous use cyclosporin , tacrolimus , antiTNF therapy , biologics , include antiintegrin antibody ( approved investigational ) , JAK inhibitor ( approved investigational ) , current previous use investigational agent within 5 halflives agent first study agent injection . Contraindication antiTNF therapy accord drug labelling : Active infection . Nontreated latent tuberculosis . Heart failure ( NYHA : Grade III IV ) . Malignancy previous 5 year . Demyelinating neurological disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>UC , IBD</keyword>
</DOC>